HCR Wealth Advisors Has $3.90 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

HCR Wealth Advisors boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,499 shares of the medical research company’s stock after acquiring an additional 54 shares during the period. HCR Wealth Advisors’ holdings in Thermo Fisher Scientific were worth $3,902,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. WINTON GROUP Ltd bought a new stake in shares of Thermo Fisher Scientific in the second quarter valued at about $332,000. Moors & Cabot Inc. increased its holdings in shares of Thermo Fisher Scientific by 1.7% in the second quarter. Moors & Cabot Inc. now owns 3,927 shares of the medical research company’s stock valued at $2,172,000 after purchasing an additional 67 shares during the last quarter. Edgestream Partners L.P. raised its holdings in Thermo Fisher Scientific by 128.7% in the 2nd quarter. Edgestream Partners L.P. now owns 6,536 shares of the medical research company’s stock valued at $3,614,000 after acquiring an additional 3,678 shares during the period. Perennial Investment Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 10.5% in the second quarter. Perennial Investment Advisors LLC now owns 717 shares of the medical research company’s stock valued at $397,000 after buying an additional 68 shares during the period. Finally, L & S Advisors Inc raised its position in Thermo Fisher Scientific by 3.6% during the second quarter. L & S Advisors Inc now owns 2,990 shares of the medical research company’s stock valued at $1,653,000 after purchasing an additional 103 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Down 1.0 %

Shares of NYSE:TMO opened at $551.64 on Thursday. The stock has a 50 day moving average of $529.85 and a 200 day moving average of $568.13. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88. The company has a market cap of $211.00 billion, a PE ratio of 34.59, a price-to-earnings-growth ratio of 3.59 and a beta of 0.76. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm had revenue of $10.60 billion for the quarter, compared to analysts’ expectations of $10.63 billion. During the same quarter in the prior year, the firm posted $5.69 earnings per share. The company’s quarterly revenue was up .2% on a year-over-year basis. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback program on Friday, November 15th that authorizes the company to buyback $4.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 2% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the transaction, the senior vice president now owns 12,736 shares of the company’s stock, valued at approximately $7,134,197.76. The trade was a 13.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the transaction, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. This represents a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 47,150 shares of company stock valued at $25,954,465. Corporate insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on TMO shares. Stifel Nicolaus dropped their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday. Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Morgan Stanley dropped their price objective on shares of Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating on the stock in a report on Monday. Finally, Redburn Atlantic initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, October 14th. They set a “buy” rating and a $680.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $648.95.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.